NeuClone hails Stelara replica

NeuClone says pre-clinical results show the biosimilar of Janssen’s Stelara (ustekinumab) that it is developing with Serum Institute of India matches the psoriasis and Crohn’s disease brand “in both primary amino-acid sequence and three-dimensional folding”. The Australian firm is currently conducting process scale-up ahead of Phase I clinical trials scheduled for next year, while it also intends to meet with “potential commercialisation partners”.